32.71 USD
↘ 0.14 (0.43%)AT CLOSE (11:59 AM EDT)
Kodiak Sciences Inc Common Stock
KODNASDAQ • USD
32.42
↘ 0.30 (0.90%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
32.42
↘ 0.30 (0.90%)
Market: CLOSED
Kodiak Sciences Inc Common Stock (KOD) is currently trading at $32.71. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Sep 18, 2026.
Open?$32.78
High?$32.82
Low?$31.54
Prev. Close?$32.85
Volume?1.6M
Avg. Volume?641.6K
VWAP?$32.14
Rel. Volume?2.51x
Bid / Ask
Bid?$31.65 × 100
Ask?$33.50 × 4.5K
Spread?$1.85
Midpoint?$32.58
Valuation & Ratios
Market Cap?2.1B
Shares Out?62.8M
Float?31.2M
Float %?49.9%
P/E Ratio?N/A
P/B Ratio?33.65
EPS?-$3.85
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Employees
124
Market Cap
2.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-04
Address
1250 PAGE MILL RD
PALO ALTO, CA 94304
Phone: 650-281-0850
PALO ALTO, CA 94304
Phone: 650-281-0850
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?30
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.67Distress
Confidence?63%Moderate
Short InterestSqueeze Risk
Short % of Float?34.54%Squeeze Risk
Short Interest?10.8M
Days to Cover?18.5
Free Float31.2M
Avg Daily Volume584.3K
Settlement Date2026-08-31
Financial Health
Current Ratio?2.49Strong
Quick Ratio?2.49Strong
Cash Ratio?2.39Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?33.65HIGH▾
Peers100
S&P3
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-8.4CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-396.1%WEAK▾
S&P3
ROA?-94.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-159902000
Enterprise Value?$1.9B
Fundamentals ratios updated end of day